TJ Biopharma Deal History & Licensing Activity
TJ Biopharma is a life sciences. Over the past three years, TJ Biopharma has been involved in 2 licensing and acquisition transactions, with a primary focus on Antibodies (4 deals).
Deals (12mo)
1
Active Trials
0
Top Modality
Antibodies
Focus Area
Mega Deals
TJ Biopharma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving TJ Biopharma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| felzartamab | Biogen | Antibodies | Unknown | license | Apr 2026 |
| felzartamab | Biogen | Antibodies | Phase 3 | acquisition | Apr 2026 |
TJ Biopharma Pipeline Focus
Therapeutic areas and modalities where TJ Biopharma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches TJ Biopharma's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Immunology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for immunology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About TJ Biopharma Licensing & Deal Activity
TJ Biopharma is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, TJ Biopharma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for TJ Biopharma include Mega Deals (2 deals and trials), and Immunology (2 deals and trials). In terms of modality, TJ Biopharma has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for TJ Biopharma and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against TJ Biopharma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.